This bill revises the Living Organ Donation Reimbursement Program in section 377 of the Public Health Service Act. It removes strict income limits by requiring grant recipients to serve donating individuals whose household income is at or below 700 percent of the HHS poverty guidelines, establishes a $10,000 per-donor reimbursement cap for FY2027 with annual CPI adjustments thereafter, and expands the program’s authorization and reporting obligations.
For compliance officers, transplant program leads, and federal grant managers, the bill changes who can receive reimbursement, how much they can get, and what the Department of Health and Human Services must track and publish annually. It also tasks the Government Accountability Office with studying whether Medicare can assume costs now paid by the grant program and to recommend statutory changes if needed.
At a Glance
What It Does
Requires grant recipients to treat donors with household income up to 700% of the HHS poverty guidelines as eligible and caps reimbursements at $10,000 in FY2027, with future caps indexed to the CPI; allows the Secretary to temporarily lower the cap if grant funds run short with 30 days’ congressional notice. It also converts an old fixed appropriations line to 'such sums as necessary' for FY2028–2037 and tightens annual reporting requirements.
Who It Affects
Primary obligations fall on HHS/HRSA (as program steward), current and future recipients of section 377 grant awards (transplant centers, nonprofit intermediaries), and living organ donors seeking reimbursement; Medicare and federal budget analysts are affected by the GAO study mandate.
Why It Matters
The changes expand practical access to donor reimbursement and create a stable, inflation‑adjusted ceiling, which may increase living donations but also raises budget and implementation questions for grant administrators and HHS. The GAO study signals congressional interest in shifting some costs to Medicare under existing law.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill amends section 377 to broaden eligibility and standardize reimbursement. Specifically, it inserts two new subsections.
The first bars grant recipients from denying reimbursement to a donor whose household income is at or below 700 percent of the HHS poverty guideline, which is the federal poverty measure published annually by HHS. That change effectively removes many prior income caps used by some programs and requires grant administrators to accept a much wider income range when determining who qualifies.
The second addition fixes the reimbursement mechanics. For FY2027 the bill sets the maximum reimbursement per donating individual at $10,000.
For later years the maximum rises automatically by the percentage change in the Consumer Price Index for All Urban Consumers (CPI‑U), rounded to the nearest hundredth. The Secretary may lower that maximum for a fiscal year if a grant recipient lacks sufficient funds, but only after determining insufficiency and providing Congress a written notice at least 30 days before the change takes effect.
Any donor approved before the notice remains unaffected, and future CPI adjustments ignore any temporary lowered cap.Congress also replaces the old fixed-dollar authorization with a “such sums as necessary” authorization for fiscal years 2028 through 2037, giving HHS more flexibility to seek funding. The annual reporting duty is expanded: HHS must publish a December 31 report starting in FY2027 that not only states whether grants provided adequate funding but includes granular metrics — applicants and approvals, average and median payouts, disaggregated expense and organ-type data, administrative vs. reimbursement expenditures, demographic breakdowns, estimates of Medicare savings, and identified barriers to eliminating financial disincentives.Finally, the bill directs the Comptroller General to study, within one year of enactment, how the Medicare program could pay costs that the Living Organ Donation Reimbursement Program currently covers, and to recommend statutory changes if necessary.
That GAO deliverable is designed to inform whether federal health insurance can absorb some donor-related costs and reduce reliance on the grant program.
The Five Things You Need to Know
The bill requires grant recipients to accept donors for reimbursement whose household income is at or below 700% of the HHS poverty guideline.
It sets a per-donor reimbursement cap of $10,000 for fiscal year 2027 and thereafter indexes the cap annually to CPI‑U percentage changes.
The Secretary may lower the cap for a fiscal year if a grant recipient lacks funds, but must give Congress written notice at least 30 days before the change and cannot claw back payments already approved.
Congressional authorization language is changed from a fixed $5 million-era line to 'such sums as may be necessary' for fiscal years 2028–2037.
HHS must produce an extensive annual report (due each December 31 beginning FY2027) with program metrics and estimates of Medicare savings, and GAO must, within one year, study whether Medicare could cover costs now paid by the grant program.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Income-based eligibility—donors up to 700% of poverty
This inserted subsection prohibits grant recipients from imposing income-based eligibility limits on donors whose household income is at or below 700 percent of the HHS poverty guideline. Practically, recipients that currently cap eligibility at much lower thresholds must accept a wider range of donors. The statutory reference to the HHS poverty guideline gives HHS a clear benchmark for administration and verification, but it places the burden on recipients to develop intake processes that reliably document household income to this relatively high threshold.
Per-donor reimbursement cap and indexing
Subsection (g) defines reimbursement as the lesser of actual qualifying expenses and a maximum permissible amount: $10,000 in FY2027, then CPI‑U adjusted in subsequent years. This creates a predictable ceiling for budgeting and for donors to expect, while capping federal exposure per donor. The indexing clause reduces the need for frequent statutory updates but ties program growth to inflation rather than demonstrated program need or donor cost trends.
Secretary’s temporary reduction authority and protections
If a grant recipient lacks funds, the Secretary can lower the maximum permissible reimbursement for that recipient for a fiscal year. Before doing so, the Secretary must determine insufficiency and provide Congress 30 days' written notice that includes justification. The provision protects donors approved before the effective date from retroactive reductions and ensures future CPI adjustments ignore any temporary lowered cap. Operationally, this forces grant recipients to track projected reimbursements and communicate funding shortfalls early.
Authorization of appropriations updated
The bill replaces a prior fixed authorization (an older $5 million benchmark) with an open-ended 'such sums as may be necessary' authorization for FY2028–2037. That change removes an outdated numeric authorization and signals congressional intent that funding should be scalable. It does not itself appropriate funds, but it allows appropriators greater leeway to allocate amounts aligned with program demand and the new per-donor cap.
Expanded annual reporting and GAO study on Medicare
The reworked annual-reporting subsection requires HHS to submit detailed, public reports each December 31 starting in FY2027. Reports must include program adequacy, counts of unreimbursed donors, funding needed to fully reimburse donors, expenditure breakdowns (administration vs. reimbursements), demographic data, expense and organ-type disaggregation, and estimates of Medicare savings tied to the program. Separately, the bill requires GAO to study within one year whether Medicare could cover costs the grant program pays now, and to recommend statutory changes to achieve that outcome. Together, these provisions increase transparency and create a direct analytical pathway for shifting program costs into Medicare if feasible.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Living organ donors with household income up to 700% of the poverty guideline — they become categorically eligible for reimbursement through grant-funded programs and face a clear, inflation‑indexed per-donor ceiling.
- Transplant centers and nonprofit intermediaries that assist donors — broader eligibility may increase the pool of donors who receive financial support, potentially reducing financial barriers to donation and improving donor retention and logistics.
- Health policy analysts and federal budget staff — the bill’s reporting and GAO study produce richer data to evaluate program effectiveness and potential Medicare cost‑sharing.
- Potential transplant recipients and health systems — if the expanded reimbursement increases living donations, waitlist time and costs associated with prolonged dialysis or deceased-donor delays could fall, producing downstream savings.
Who Bears the Cost
- HHS/HRSA and grant recipients — they must administer expanded eligibility, process more applications, and comply with more detailed reporting requirements, which increases administrative workload and may require additional staffing or systems.
- Federal appropriations — the 'such sums as necessary' authorization and higher per-donor ceilings expose appropriators to potentially larger budgetary requests, particularly if demand grows or the GAO recommends Medicare changes that require transition funding.
- Grant recipients experiencing demand spikes — recipients that exhaust funds may see reduced per-donor caps under the Secretary’s insufficiency authority, complicating donor communications and program planning.
- Medicare (potentially) — the GAO study could lead to policy shifts that move some donor-related costs into Medicare; if implemented, Medicare would face new payment obligations absent offsetting savings or statutory payment rules.
Key Issues
The Core Tension
The central dilemma is between eliminating financial disincentives to living organ donation by broadly expanding eligibility and maintaining fiscal and administrative sustainability: widening access and indexing payouts encourages more donors but increases program demand and budgetary exposure, while caps, temporary reductions, and funding uncertainty protect federal outlays but can leave donors partially unreimbursed and administrators with hard allocation choices.
The bill materially widens eligibility while instituting a per-donor cap tied to CPI. That combination raises a classic policy tension: broader access increases program demand and administrative load, while a fixed or capped payment mechanism limits federal exposure but can leave donors partially uncompensated.
The Secretary’s authority to lower the cap for recipients with insufficient funds mitigates catastrophic shortfalls but introduces variable reimbursement risk that could discourage donors or complicate recipient planning. The 30‑day congressional notice offers transparency but may not be adequate for recipients or donors to adapt operative practices mid‑fiscal year.
Operationally, the move to an income threshold of 700% of poverty simplifies statute but pushes verification complexity onto recipients who must collect reliable household income data across varied donor circumstances. The CPI indexing stabilizes purchasing power but may not track specific donor expense growth (for example, travel and lodging vs. medical costs) and therefore could under- or over-compensate over time.
Finally, the GAO study focuses congressional attention on Medicare as a possible payer, but transitioning costs to Medicare raises legal and policy questions (eligibility, benefit design, potential interactions with existing prohibitions on donor compensation) that GAO may address but which could require separate statutory fixes and appropriation choices.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.